Status:
COMPLETED
Efficacy and Safety of Low-dose Ticagrelor
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Collaborating Sponsors:
Beijing Anzhen Hospital
The First Affiliated Hospital of Dalian Medical University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patie...
Detailed Description
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly u...
Eligibility Criteria
Inclusion
- Patients with coronary artery disease
Exclusion
- younger than 18 years of age;
- anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;
- previous or current treatment with any other potentially confounding drugs.
Key Trial Info
Start Date :
December 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2019
Estimated Enrollment :
3043 Patients enrolled
Trial Details
Trial ID
NCT03381742
Start Date
December 13 2017
End Date
February 13 2019
Last Update
September 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thromboela-Stogram
Beijing, China, 100001